Compound reference
This combination brings together BPC-157, TB-500. Explore each component’s research focus below, followed by the evidence for the combination.
BPC-157 is studied for processes involved in tendon and connective-tissue repair, including collagen organization and cellular responses to injury. The potential application is tissue recovery, supported here by preclinical findings rather than established clinical benefits.
Full-length thymosin beta-4 is studied for cell movement and tissue-repair signaling. These pathways explain interest in recovery biology, while molecular identity and direct clinical evidence remain essential to interpreting potential applications.
Explore the selected studies, their findings and their limits.
A rat Achilles-tendon injury experiment reported improved tendon strength, functional measures and collagen organization with BPC-157 compared with controls. A separate study in rat tendon fibroblasts found increased growth-hormone receptor expression. Together, these findings explain interest in tissue-repair signaling, but neither study demonstrates healing, pain relief or safety in people or dogs.
The name TB-500 can refer to different materials. Research on full-length thymosin beta-4 found directional migration of cultured human endothelial cells, which line blood vessels. This supports investigation of actin-related cell movement and tissue biology. It does not establish injury recovery in humans or dogs. The name TB-500 is also used for a shorter fragment, so full-length and fragment findings must remain separate.
The sources above examine individual constituents or related molecules. They do not test this exact combination. A combined effect, improved recovery or greater safety cannot be inferred by adding the individual findings together.
The studies discussed here do not establish the safety or effectiveness of this catalog formula in dogs. Rat, mouse, cell-culture and human findings are not canine clinical results; they also do not establish absorption or effects from the listed oral formula.
For more information, contact info@aurevixpeptides.com.
Editorial review: September 23, 2026
